Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotine Dermal Patch for Classical Kaposi Sarcoma
NCT00295984Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nicotine in Kaposi sarcoma (KS), sponsored by National Cancer Institute. Primary endpoint: Tumor response at 15 weeks. Started Mar 2006; status: completed.
02
Drugs
nicotine
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT00295984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00295984.